The Only Known Natural NGF Stimulator
Among the hundreds of compounds studied for brain health in aging mammals, lion’s mane mushroom (Hericium erinaceus) holds a singular distinction: it contains compounds — hericenones and erinacines — that cross the blood-brain barrier and stimulate the synthesis of nerve growth factor (NGF). No other known natural compound does this.
This is relevant because canine cognitive dysfunction syndrome (CDS) affects an estimated 28% of dogs aged 11-12 and over 68% of dogs aged 15-16. The condition involves progressive neurodegeneration, beta-amyloid plaque accumulation, and declining neurotrophic support — a pattern strikingly similar to Alzheimer’s disease in humans. NGF is one of the neurotrophins that declines with age, and its depletion is directly implicated in cognitive deterioration.
How Hericenones and Erinacines Work
Lion’s mane produces two families of bioactive compounds with distinct but complementary neurological effects.
Hericenones (found in the fruiting body) stimulate NGF production in astrocytes. NGF is critical for the survival and function of cholinergic neurons — the same neuron population that degenerates in both canine CDS and human Alzheimer’s. A 2013 review in Mycological Research confirmed that hericenones induce NGF synthesis in a dose-dependent manner.
Erinacines (found primarily in the mycelium) are smaller molecules that cross the blood-brain barrier more readily and stimulate NGF synthesis from within the central nervous system. A 2016 study in Behavioural Neurology demonstrated that erinacine-enriched mycelium reduced beta-amyloid plaque burden and improved cognitive performance in rodent models of neurodegeneration.
The two compound families work through different pathways, which is why some researchers argue that a product containing both fruiting body and mycelium extracts may be more effective than either alone.
The Evidence for Cognitive Support
Human clinical trial. A 2009 double-blind, placebo-controlled trial in Phytotherapy Research gave lion’s mane to elderly subjects with mild cognitive impairment. After 16 weeks, the supplemented group showed significantly improved cognitive function scores compared to placebo. Notably, cognitive scores declined again after supplementation stopped, suggesting ongoing supplementation is necessary.
Canine cognitive dysfunction and NGF. A 2004 study in Progress in Neuro-Psychopharmacology and Biological Psychiatry established that NGF levels decline in the brains of dogs with CDS, and that this decline correlates with the severity of cognitive symptoms. This creates a direct mechanistic link: if lion’s mane raises NGF levels, it could slow or partially reverse the NGF deficit driving CDS progression.
Hippocampal function. A 2017 study demonstrated that dietary lion’s mane supplementation enhanced hippocampal neurotransmission in the mossy fiber-CA3 pathway — a circuit critical for spatial memory and learning. Dogs with CDS commonly show spatial disorientation (getting stuck behind furniture, pacing, failing to recognize familiar routes), which maps to hippocampal dysfunction.
No published canine clinical trials exist. The evidence chain is: (1) lion’s mane stimulates NGF, (2) NGF declines in canine CDS, (3) NGF restoration improves cognitive outcomes in rodent models, (4) human trials show cognitive benefits. The biological plausibility is strong, but direct canine efficacy data is missing.
Dosing Guidelines
For standardized extract (fruiting body or dual-extracted):
- Small dogs (under 10 kg): 150-300 mg daily
- Medium dogs (10-25 kg): 300-750 mg daily
- Large dogs (over 25 kg): 750-1,500 mg daily
For whole mushroom powder:
- Approximately double the above doses
Product selection factors:
- Look for products that contain both hericenones (fruiting body) and erinacines (mycelium), or choose a dual-extract
- Avoid “mycelium on grain” products without standardized compound levels
- Third-party testing for identity and contaminants
- Some products standardize to beta-glucan content; for lion’s mane specifically, hericenone/erinacine content is more relevant than beta-glucan percentage
Safety Considerations
Lion’s mane has an excellent safety profile with no reported toxicity in animal studies even at high doses. Considerations include:
- GI tolerance: Mild digestive upset is possible during the first week. Introduce gradually.
- Anticoagulant interaction: Lion’s mane has mild antiplatelet effects in vitro. Caution with concurrent blood thinning medications; discontinue 7-10 days before surgery.
- Immune effects: Unlike reishi and turkey tail, lion’s mane is not a strong immune stimulator, making it a better option for dogs with autoimmune conditions who still need neuroprotective support.
- No known drug interactions with common CDS medications (selegiline/Anipryl), though concurrent use has not been formally studied.
When to Consider Lion’s Mane
The strongest rationale for lion’s mane supplementation in dogs is early cognitive decline — specifically when you first notice signs like nighttime restlessness, spatial confusion, altered sleep-wake cycles, or reduced engagement. Starting supplementation before severe neurodegeneration occurs gives NGF-mediated neuroprotection the best chance of meaningful impact.
For breeds predisposed to degenerative myelopathy, the nerve growth factor mechanism is also theoretically relevant, though no studies have evaluated this specific application.
Related reads: Phosphatidylserine for Dogs, Cognitive Health Nutrition for Dogs, Canine Cognitive Decline Early Action Plan, SAM-e for Dogs
Frequently Asked Questions
Can lion’s mane help dogs with dementia? Canine cognitive dysfunction syndrome shares key features with human dementia, including NGF depletion, beta-amyloid accumulation, and cholinergic neuron loss. Lion’s mane stimulates NGF synthesis, which directly targets one of these degenerative pathways. A human clinical trial showed measurable cognitive improvement after 16 weeks, and the biology is conserved across mammals. No canine clinical trials have been published, but for breeds with high CDS prevalence — such as senior Beagles, Cocker Spaniels, and Toy Poodles — the mechanistic rationale is strong enough to warrant consideration alongside other cognitive support strategies.
Is lion’s mane safe for dogs? Lion’s mane has an excellent safety profile with no reported toxicity. It is less immunostimulatory than other medicinal mushrooms, making it suitable for a wider range of dogs, including those with autoimmune conditions. Mild GI upset during initial supplementation is the most commonly reported side effect.
Should I use fruiting body or mycelium lion’s mane? Ideally, a product containing both. Hericenones (fruiting body) and erinacines (mycelium) stimulate NGF through different pathways. Some researchers suggest dual-source products may be more effective, though direct comparison studies are lacking.
How long does lion’s mane take to work? The human clinical trial showed cognitive improvements after 8-16 weeks of daily supplementation, with scores declining again when the supplement was discontinued. This reversal suggests that ongoing daily administration is necessary to maintain benefit. In dogs, a reasonable evaluation period is 8-12 weeks of consistent dosing before assessing whether nighttime restlessness, spatial confusion, or engagement have improved. Keep a simple log of behaviors to track changes objectively rather than relying on memory.
Can I give lion’s mane with Anipryl (selegiline)? No formal interaction studies exist, but the mechanisms are different (MAO-B inhibition vs. NGF stimulation). Some integrative veterinarians use both concurrently. Discuss with your veterinarian before combining.
References
- Hericenones and erinacines: NGF biosynthesis stimulators (Mycol Res, 2013)
- Lion’s mane improves mild cognitive impairment: RCT (Phytother Res, 2009)
- Erinacine-enriched mycelium and neuroprotection (Behav Neurol, 2016)
- NGF and canine cognitive dysfunction syndrome (Prog Neuropsychopharmacol Biol Psychiatry, 2004)
- Lion’s mane enhances hippocampal neurotransmission (Evid Based Complement Alternat Med, 2017)